🇺🇸 Urografin in United States
26 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 26
Most-reported reactions
- Febrile Neutropenia — 6 reports (23.08%)
- Hypotension — 3 reports (11.54%)
- Pneumonia — 3 reports (11.54%)
- Bleeding Varicose Vein — 2 reports (7.69%)
- Cholangitis Acute — 2 reports (7.69%)
- Foaming At Mouth — 2 reports (7.69%)
- Portal Hypertension — 2 reports (7.69%)
- Pulse Absent — 2 reports (7.69%)
- Pyrexia — 2 reports (7.69%)
- Tumour Lysis Syndrome — 2 reports (7.69%)
Other Other approved in United States
Frequently asked questions
Is Urografin approved in United States?
Urografin does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Urografin in United States?
Hvidovre University Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.